Seattle Genetics: Good News On The Horizon?

Seattle Genetics discontinued a late-stage study of an experimental leukemia drug, but this analyst says investors should buy on weakness. Here’s why.
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>